Business Context and Reporting Period
This Form 8-K Current Report, dated September 29, 2025, details a material definitive agreement entered into by Artelo Biosciences, Inc. (Nasdaq: ARTL). The report covers the execution of an Underwriting Agreement on September 30, 2025, and the subsequent closing of an underwritten public offering on October 1, 2025.
Key Financial Metrics and Offering Details
The filing discloses the following specific financial terms regarding the capital raise:
- Gross Proceeds: Approximately $2 million.
- Securities Issued:
- 441,210 shares of Common Stock at $4.40 per share.
- 13,335 Pre-funded Warrants at $4.399 per warrant (exercisable at $0.001 per share).
- Over-Allotment Option: The underwriter (R.F. Lafferty & Co., Inc.) holds a 45-day option to purchase up to an additional 68,181 shares or pre-funded warrants.
- Use of Proceeds: Funds are designated for advancing product candidates through preclinical and clinical development, manufacturing, research, capital expenditures, and working capital.
Note: This filing does not provide historical revenue, profit, cash flow, margin, or debt figures. It is a transactional report rather than a periodic financial statement.
Material Changes and Agreements
The primary material change is the execution of the Underwriting Agreement and the resulting equity issuance. Key contractual terms include:
- Lock-Up Agreements: Directors and executive officers are restricted from selling securities for 30 days following the Underwriting Agreement date.
- Issuance Restrictions: The Company is prohibited from issuing new equity or equity-linked securities for 30 days from the Closing Date without underwriter consent.
- Right of First Refusal: The underwriter was granted exclusive rights to act as investment banker or underwriter for future equity and debt offerings until December 31, 2025.
- Ownership Limitation: Pre-funded warrant holders are subject to a 9.99% beneficial ownership limit unless they provide 61 days' prior notice to increase it.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to accelerate the development pipeline and general corporate purposes. The filing includes standard forward-looking statements cautioning that actual results may differ materially from expectations due to risks inherent in clinical development and capital markets. No specific financial guidance or quantitative outlook was provided in this document.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and commissions, as only gross proceeds (~$2 million) are stated.
- Confirm the exact number of shares outstanding post-closing to assess dilution impact.
- Review the attached press releases (Exhibits 99.1, 99.2, 99.3) for specific details on the pricing rationale and market conditions.
- Monitor the exercise of the 45-day over-allotment option by the underwriter.
- Check subsequent filings for updates on the deployment of capital into specific clinical trials or product candidates.